RecruitingPhase 1NCT07652281

A Clinical Study of SHR-5421 in Patients With Multiple Myeloma

An Open-label, Multicenter, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SHR-5421 in Patients With Multiple Myeloma

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrollment

97 participants

Start Date

Jul 23, 2026

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-5421 in patients with multiple myeloma (MM).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-5421 for Injection for people with multiple myeloma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.